Asking
Asking
Grasping
Coping

News Flash 3.2015

In February 2015, the FDA granted accelerated approval for a new drug, Palbociclib (Ibrance), for the treatment of post-menopausal women with advanced breast cancer whose tumors are hormone receptor positive and HER-2 negative.
Defined as a breakthrough therapy among these patients, Palbociclib, given as tablets, signals a new strategy for arresting cell tumor growth. In a study addressing this issue, patients receiving Palbociclib in combination with anti-hormonal therapy responded better and for a much longer time compared to those receiving anti-hormonal therapy alone. Nevertheless, Palbociclib also has side effects.
At the moment, Palbociclib is still not approved by the Israeli drug panel as state-subsidized for the treatment of patients with advanced breast cancer. 

Accessibility Toolbar